Articles and Insights About Wearables for Clinical Trials

VivoSense, Inc. has joined the Clinical Trials Transformation Initiative (CTTI) to advance the efficiency and efficacy of clinical trial research and care. As a leading provider of digital endpoint solutions derived from wearable sensors, VivoSense will contribute to CTTI's foundational efforts to improve quality, patient engagement, novel trial design, digital health trials, investigator, and site support and ethics in research.

At the a2 National Symposium: Empowering Innovation in AI/Tech + Aging, Senior Research Scientist Jen Blankenship, PhD, presented our ongoing work with the Center for Human Health and Performance at the University of Massachusetts Amherst to develop digital clinical measures that capture how patients with Alzheimer’s disease function in their real-world environments. 

VivoSense announces an expansion of our collaboration with the Rett Syndrome Research Trust (RSRT). Building on the success of our previous collaborations, VivoSense and RSRT will continue to support the development of treatments for Rett Syndrome (RTT) by qualifying objective digital outcome measures of breathing problems for use in RTT trials.

VivoSense recognizes Rare Disease Day by minding the importance of discovering new advancements in research and clinical trials to care for those with rare diseases. There are approximately 30 million Americans living with rare diseases today, and research into new therapies is imperative for these patients.

#scope2023 is living up to its mission of driving innovation in clinical trials. Here are a few key takeaways that stood out from the expert panel at the Novel Evidence for Regulatory Success breakout session.

We are excited to announce our participation in the Digital Medicine Society's (DiMe) latest digital clinical measures project, Core Measures of Sleep. In partnership with the Digital Medicine Society and other leaders in the field, we are paving the way for better approaches to collecting, analyzing, and interpreting sleep data.

VivoSense, a trusted leader in the development, validation, and delivery of digital clinical measures, announced today that it has been awarded a research grant funded by the National Institute of Aging (NIA) and the Massachusetts Artificial Intelligence and Technology Center for Connected Care in Aging & Alzheimer’s Disease (MassAITC; grant number 5P30AG073107-02 Pilot A2).

Movement and mobility-related information collected passively and continuously from digital health technologies (DHTs) as patients go about their daily lives can significantly advance our understanding of patient functioning. The Best 6-Minute Effort (B6ME)™ is a novel outcome measure that captures the maximum effort exerted by a patient as they go about their typical daily life, providing insight into their lived experience.

Here's an overview of what B6ME™ is and how it augments the 6MWT to provide additional granularity of patient functioning and novel movement and mobility-related outcomes.

Alzheimer’s disease (AD) is a devastating neurodegenerative disease that progresses to impact every dimension of a patient’s life. With no cure and limited options to manage symptoms, research is underway to develop drugs that impact the most burdensome aspects of AD: memory problems and the ability to function independently.

Good data is more important than big data in developing digital biomarkers. Big data is often sold as the solution to all digital data analyses and is touted to revolutionize healthcare in the coming years. However, the problem with a superabundance of data is that digital biomarker development becomes a fishing expedition, and the catch may not be relevant to the question. Without a hypothesis (often the case in biomarker development with big data), accurate results may be too low to use in a clinical trial or, even worse, divergent with no findings.